Influence of hemorheological factors on the development of retinal vein occlusion

Michalska-Małecka, Katarzyna; Śpiewak, Dorota; Słowińska-Łożyńska, Ludmiła; Sierocka-Stępień, Justyna

doi:10.3233/ch-162056

Cited by 7 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fifty-five patients (61.1%) had hypertension, while 14 patients (15.6%) had type 2 diabetes but no diabetic retinopathy (DR). The mean Hb level was 160±25.8 g/L (range, 82-255 g/L), while the mean RBC count was (5.4±0.8)×10 9 /L (range, 3.9-9.1). The mean Hb level of the men was significantly higher than that of women.…”

Section: Subjects and Methods Ethical Approvalmentioning

confidence: 99%

“…11, Nov.18, 2022 www.ijo.cn Tel: 8629-82245172 8629-82210956 Email: ijopress@163.com (Hb), the increase of blood viscosity and blood stasis, and so on [5][6][7][8] . These changes may account for the higher incidence of RVO in TAR [9] . On the other hand, there is growing evidence on association between systemic adverse events (SAEs) related to anti-VEGF therapy (cerebral infarction, myocardial infarction, etc.)…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Real-world outcomes of anti-vascular endothelial growth factor therapy for retinal vascular vein occlusion in Tibet, China

Zhu¹,

Zhuoga²,

Dawa³

et al. 2022

Int J Ophthalmol

View full text Add to dashboard Cite

AIM: To evaluate the outcomes of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents for patients with retinal vein occlusion (RVO) related-macular edema (ME) in Tibetan. METHODS: A retrospective, observational, single-center study. The demographic and clinical data of 90 RVO Tibetan patients (93 eyes) treated with either ranibizumab or conbercept in Tibet Autonomous Region People’s Hospital from Jan 2018 to December 2019 were collected. RESULTS: The mean patient age was 56.8±10.6y, 45 (50%) of them were female. The mean living altitude was 3867.8±567.9 m. At the last visit, the best-corrected visual acuity (BCVA) significantly increased (52.2±21.8 letters) in comparison with the baseline (38.2±24.1 letters, P<0.001); while the central retinal thickness (CRT) significantly reduced (245.5±147.6 μm) in comparison with the baseline (504.1±165.2 μm, P<0.001). The 43.0% of the eyes gained ≥15 letters, 60.2% of the eyes gained ≥10 letters, and 78.5% of the eyes gained ≥5 letters. No vision loss was noted in 92.5% of the eyes, 4 eyes lost more than 10 letters during follow-up period. The mean number of injections was 2.4±1.8. No severe ocular or systemic adverse events related to either the drug or injection were noted. CONCLUSION: Anti-VEGF therapy is effective and safe in Tibetan patients for the treatment of RVO related ME.

show abstract

Section: Subjects and Methods Ethical Approvalmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%

Real-world outcomes of anti-vascular endothelial growth factor therapy for retinal vascular vein occlusion in Tibet, China

Zhu¹,

Zhuoga²,

Dawa³

et al. 2022

Int J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Increased viscosity of blood creates the risk of CRVO and hemostasis abnormalities promote the development of neovascularization. 12 , 13 …”

Section: Introductionmentioning

confidence: 99%

“…Increased viscosity of blood creates the risk of CRVO and hemostasis abnormalities promote the development of neovascularization. 12,13 In retinal venous thrombosis, corticosteroids reduce macular oedema, inhibit expression of endothelial growth factor (VEGF), 14,15 reduce the formation of mediators of cystic macular oedema, 16,17 stabilize the blood-retinal barrier and improve hemorheological parameters in retinal vessels. The administration of corticosteroid directly to the vitreous chamber allows to achieve the optimal therapeutic concentration in the eye tissues.…”

Section: Introductionmentioning

confidence: 99%

Effect of a Dexamethasone Implant on Rheological Blood Parameters in Patients Treated for Retinal Vein Thrombosis

Śpiewak¹,

Heinke²,

Michalska-Małecka³

2022

IJGM

Self Cite

View full text Add to dashboard Cite

Purpose To assess the effect of the prolonged-release dexamethasone implant (Ozurdex) in patients with retinal venous thrombosis on blood rheological parameters and evaluate the impact on morphological and functional parameters. Methods Prospective cross-sectional study involved 35 subjects treated with central retinal vein and vein branch occlusion with intravitreal dexamethasone implant and 35 healthy subjects in control group. Hematocrit, blood and plasma viscosity, erythrocyte aggregation amplitude (EAA), index (EAI), aggregation half-life time (EAT1/2), and erythrocyte deformability (ED) were evaluated. The best-corrected visual acuity (BCVA), central retinal thickness (CRT) and visual field (VF) were examined. All the parameters were examined at the baseline, 7 and 30 days after the treatment. The results were analyzed with correlation and regression and compared to the baseline values. Results In the studied group, three hemorheological parameters improved as early as on the 7th day after the drug administration, and this improvement remained at a similar level on the 30th day. The EAA increased by 21.26% on day 7 and by 19.78% on day 30, the EAI decreased by 10.55% on day 7 and by 9.14% on day 30 and the EAT1/2 time increased by 38.50% on day 7 and by 31.02% on day 30. On day 7, the BCVA was improved by 1 row, CRT was reduced by 170.77 µm (24.49%), and the VF was improved by 9.8 dB (49.92%) compared to baseline parameters. On day 30, the BCVA was improved by three rows, CRT reduced by 244.68 µm (35.09%), and VF improved by 12.09 dB (61.59%). Conclusion The intravitreal dexamethasone implant used in treating macular oedema in patients with RVO has a statistically significant effect on some rheological parameters of blood, reduction of CRT and clinical improvement in BCVA and VF.

show abstract

“…To reveal the pathophysiology of different types of RVO, investigation of systemic conditions combined with RVO may provide useful clues. Thus far, the development of RVO has been associated with obesity, smoking, and hemorheological factors [4–6]. Systemic conditions have been also reported as risk factors, such as hypertension, diabetes, dyslipidemia, and other cardiovascular diseases [7].…”

Section: Introductionmentioning

confidence: 99%

Comparison of systemic conditions at diagnosis between central retinal vein occlusion and branch retinal vein occlusion

Cho¹,

Bae²,

Park³

et al. 2019

PLoS ONE

View full text Add to dashboard Cite

Objective To compare systemic conditions at the time of diagnosis between patients with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). Design This study included patients diagnosed with CRVO or BRVO between February 2009 and August 2017 at three branch hospitals of Hallym University Medical Center. Demographic and anthropometric variables, systemic comorbidity profiles, and laboratory findings at diagnosis were collected from a clinical data warehouse system, and were compared between the CRVO and BRVO groups. Result Four hundred and seventeen patients with CRVO and 1,511 patients with BRVO were included. The mean age was 61.8 ± 13.9 years, which was comparable between two groups ( P = .332). Female proportion was higher in the BRVO group (55.0%) than in the CRVO group (48.0%; P = .013). Diabetes mellitus ( P = .017) and chronic kidney disease ( P = .004) were more prevalent in the CRVO group. Serum homocysteine level was abnormally high in 23.5% of CRVO patients and in 8.4% of BRVO patients ( P < .001). Blood urea nitrogen and serum creatinine levels were abnormally elevated in more subjects with CRVO ( P = .002). Conclusion CRVO is associated with higher prevalence of diabetes mellitus and chronic kidney disease, as well as with elevated serum homocysteine level. These results might suggest a difference between the pathophysiologies of CRVO and BRVO.

show abstract

Influence of hemorheological factors on the development of retinal vein occlusion

Cited by 7 publications

References 18 publications

Real-world outcomes of anti-vascular endothelial growth factor therapy for retinal vascular vein occlusion in Tibet, China

Real-world outcomes of anti-vascular endothelial growth factor therapy for retinal vascular vein occlusion in Tibet, China

Effect of a Dexamethasone Implant on Rheological Blood Parameters in Patients Treated for Retinal Vein Thrombosis

Comparison of systemic conditions at diagnosis between central retinal vein occlusion and branch retinal vein occlusion

Contact Info

Product

Resources

About